News of Note—Merck petition, GeoVax partnership and more


Here is some other vaccine news of note for the week:

> A petition challenging Merck's decision to phase out a RotaTeq supply deal for four African countries has generated nearly 50,000 signatures. Petition | FiercePharma article

> GeoVax signed a partnership with Virometix to develop a therapeutic HPV vaccine. Release


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

> Initial data for NantKwest's cancer vaccine left analysts confused about the candidate's potential benefit. FierceBiotech article

> ImmusanT started a phase 2 study for its celiac disease vaccine. Release (PDF)

> With support from the Gates Foundation, InDevR will apply its VaxArray potency testing platform to measles and rubella vaccines. Release


Suggested Articles

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.

CanSino and its partners won a go-ahead to move a recombinant coronavirus vaccine into phase 1 testing in Wuhan, China, once the outbreak's center.